Overview

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Status:
Terminated

Trial end date:
2010-10-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Zealand University Hospital

Treatments:

Alfacalcidol
Ergocalciferols
Hydroxycholecalciferols

Criteria

Inclusion Criteria:

1. >18 years old

2. Secondary hyperparathyroidism; iPTH > 350 pg/ml before any treatment or after 6 weeks
without any treatment with vitamin D.

3. Chronic renal insufficiency receiving hemodialysis.

4. P-phosphate < 1,8 mmol/l

5. P-calcium ion < 1,25 mmol/l

6. Receiving maximal possible dose of calcium-based phosphate binder.

7. Accepting 2 x 6 weeks without vitamin D.

8. Safe anti conception in fertile women

9. Do not expect need of calcimimetics or parathyroidectomy during the next year.

10. Written informed consent.

Exclusion Criteria:

1. Malignancy

2. Disease or condition making the patient unable to participate

3. Expected lifetime less than one year.

4. Pregnancy and nursing

5. Allergic to contents of Zemplar or Etalpha

6. Currently receiving calcimimetics

7. Participating in other clinical intervention studies